Critical appraisal of temozolomide formulations in the treatment of primary brain tumors: patient considerations

Margarita García1 Clinical Research Unit, Institut Català d’Oncologia-IDIBELL, L’Hospitalet, Barcelona, Spain;Correspondence[email protected]

Ana Clopés2 Pharmacy Department, Institut Català d’Oncologia-IDIBELL, L’Hospitalet, Barcelona, Spain;

Jordi Bruna3 Neurology Department and Neuro-Oncology Unit, Hospital Universitario de Bellvitge-IDIBELL, L’Hospitalet, Barcelona, Spain;

María Martínez4 Oncology Department, Hospital del Mar, Barcelona, Spain;

Eduard Fort2 Pharmacy Department, Institut Català d’Oncologia-IDIBELL, L’Hospitalet, Barcelona, Spain;

Miguel Gil5 Oncology Department and Neuro-Oncology Unit, Institut Català d’Oncologia-IDIBELL, L’Hospitalet, Barcelona, Spain

Your download is now in progress and you may close this window